Atara Biotherapeutics Inc. diskutieren
Atara Biotherapeutics Inc.
WKN: A1166A / Name: Atara / Aktie / Biotechnologie & medizinische Forschung / Small Cap /
Atara, leader in allogeneic T-cell immunotherapy
This leader in allogeneic T-cell immunotherapy has a promising lead drug candidate and several irons in the fire.
ATA129 is being evaluated in dual pivotal studies to treat cancer patients with rituximab-refractory EBV-PTLD and has exhibited encouraging data to date.
Promising early results were observed in refractory nasopharyngeal carcinoma, and a phase 1/2 study combining ATA129 with Merck's Keytruda should be initiated soon.
ATA190 in progressive MS shouldn't be overlooked, institutional positioning bodes well, and
management has the necessary experience to get the job done.
Biotechnologie und medizinische SecteurRecherche
Secteur Recherche biotechnologique et médicale Agenda 05/04 Présentation
Neueste Beiträge
Biggybaer in Arm Holdings Plc diskutieren